Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Target Lesion Clear all
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

NCT02030860
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Paricalcitol, Abraxane, Gemcitabine
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy

NCT03044197
View directory record Official record
Conditions
Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy, Clinically Significant Prostate Cancer, Transperineal
Interventions
MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

NCT07132190
View directory record Official record
Conditions
Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions
Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
Radiation
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

Target Muscle Re-innervation and Regenerative Peripheral Nerve Interfaces Alone and in Combination for the Treatment of Residual and Phantom Limb Pain in Cancer Patients Who Have Received an Amputation

NCT06840262
View directory record Official record
Conditions
Amputation
Interventions
Questionnaire Administration, Regenerative Peripheral Nerve Interface Surgery, Targeted Muscle Reinnervation
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)

NCT05343793
View directory record Official record
Conditions
Addiction, Opioid
Interventions
Enhanced Monitoring and Feedback (EMF), NIATx/MAT Academy, NIATx-Internal Facilitation (NIATx-IF), NIATx-External Facilitation (NIATx-EF)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Olympia, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RHH646 for Knee Osteoarthritis

NCT05816395
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
RHH646, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Lincoln, California • Winter Park, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT06070012
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Tebentafusp
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

NCT02394730
View directory record Official record
Conditions
HIV
Interventions
vorapaxar, Placebo
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
40 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Georgetown, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])

NCT04403399
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
45 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression

NCT06511544
View directory record Official record
Conditions
Depression, Treatment Resistant
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance

NCT02509065
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03727022
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Placebo, SM04690
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Canoga Park, California • Carmichael, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

The Medtronic RESOLUTE US Clinical Trial

NCT00726453
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Zotarolimus-Eluting Coronary Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352
View directory record Official record
Conditions
Bone Metastases, Castration-Resistant Prostate Cancer
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733
View directory record Official record
Conditions
Alzheimer Disease
Interventions
E2814
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 22, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

NCT03756285
View directory record Official record
Conditions
Heart Failure
Interventions
AZD4831, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 22, 2026, 10:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now

NCT03728348
View directory record Official record
Conditions
Colorectal Cancer
Interventions
mt-sDNA screening test, Colonoscopy
Diagnostic Test · Procedure
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
45 Years to 49 Years
Enrollment
983 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
39
States / cities
Phoenix, Arizona • Camarillo, California • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 22, 2026, 10:24 PM EDT
Completed No phase listed Observational

Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS®) Real World Outcomes

NCT04725838
View directory record Official record
Conditions
Chronic Pain
Interventions
Medtronic Intellis™ and Vanta™
Device
Lead sponsor
Celéri Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Anchorage, Alaska • Oro Valley, Arizona • Sierra Vista, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC

NCT02658097
View directory record Official record
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, Single Fraction Radiation Therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 4 Interventional Results available

Treatments Against RA and Effect on FDG-PET/CT

NCT02374021
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Results available

Remote-delivered MBCT for SCAD Survivors

NCT04983680
View directory record Official record
Conditions
Acute Coronary Syndrome, Coronary Artery Disease, Anxiety, Sleep
Interventions
MBCT
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Increasing the Repertoire of Intermuscular Co-ordination Post Stroke Through EMG-Guided Human-Machine Interaction

NCT06523335
View directory record Official record
Conditions
Stroke
Interventions
Neuromuscular coordination-guided rehabilitative training, Force strengthening-guided rehabilitative training
Other
Lead sponsor
University of Houston
Other
Eligibility
40 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

NCT00494013
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Insulin Lispro Protamine Suspension, Detemir
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Hueytown, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2009 · Synced Oct 22, 2026, 10:24 PM EDT